Arlene O. Siefker-Radtke, MD, discusses the latest breakthroughs in bladder cancer treatment with erdafitinib, an FGFR1-4 inhibitor.
Arlene O. Siefker-Radtke, MD, professor of genitourinary medical oncology at the University of Texas MD Anderson Cancer Center in Houston, Texas, discusses the latest breakthroughs in bladder cancer treatment with erdafitinib (Balversa), an FGFR1-4 inhibitor.
The agent was recently approved by the FDA for the treatment of locally advanced or metastatic urothelial carcinoma with FGFR3 alterations with disease progression following a prior line of treatment. The approval was supported by findings from the THOR study (NCT03390504).
Transcription:
0:09 | At the moment, there are not any planned trials in the metastatic setting, however, erdafitinib is being explored in earlier-stage disease. When we look at metastatic tumors of the bladder, we see FGF alterations in 15% to 20% of patients. And in metastatic tumors of the upper tract, we see FGF alterations in over 35% of patients. When we move to earlier-stage disease, that superficial bladder cancer, we see FGF alterations in over 60% of patients. So using erdafitinib, we might be able to control or help delay recurrences and patients with superficial bladder cancer needing transurethral resection.
1:02 | At this year's ESMO meeting, we saw some first results from a randomized trial in superficial bladder cancer which compared erdafitinib vs alternative care, and it showed that erdafitinib had benefit, but it came at the cost of toxicity, [adverse] effects like hand-foot syndrome, or the risk of central serous retinopathy, which an earlier-stage disease where patients can be cured with cystectomy, most patients chose not to continue on the erdafitinib.
1:37 | However, to overcome that, there are now drug-eluting stents, so a drug-eluting pretzel, that can be placed inside the bladder, eluting erdafitinib into the bladder, creating more sustained erdafitinib levels without the systemic toxicity. I really do have high hopes for these pretzel-like structures that you can put inside the bladder, these drug-eluting strategies, which will allow us to get treatment where it is needed into that superficial urothelium without having all of those [adverse] effects of systemic therapy.
Responders to UGN-101 Have Positive RFS in Upper Tract Urothelial Cancer
May 5th 2024In patients at 15 centers who had upper tract urothelial cancer, those with no evidence of disease after UGN-101 induction had a 68% rate of 3-year recurrence-free survival, and this outcome did not differ based on tumor status, method of instillation, or treatment intent.
Read More
UGN-101 Shows Promise for Upper Tract Urothelial Cancer Durability
May 5th 2024Maintenance UGN-101 therapy demonstrated good durability of response in initial responders with low-grade upper tract urothelial cancer, as evidenced by a low rate of disease progression in a multicenter, longitudinal follow-up study.
Read More
Nivolumab With Gemcitabine-Cisplatin Boosts Survival in Metastatic Urothelial Carcinoma
May 5th 2024Combination therapy with nivolumab and gemcitabine-cisplatin showed promising results in treating metastatic urothelial carcinoma with significantly improved overall survival and progression-free survival rates.
Read More